Core Insights - Alzamend Neuro, Inc. reported financial results for the year ended April 30, 2025, highlighting a strengthened financial position and strategic focus on fiscal prudence and effective capital management [1][2] - The company successfully completed a $5 million financing ahead of schedule, which will support five Phase II clinical trials of its drug candidate AL001 in partnership with Massachusetts General Hospital and Harvard Medical School [3][4] Financial Performance - For the year ended April 30, 2025, net cash provided by financing activities was $10.4 million, with stockholder equity increasing to $4.0 million from a deficit of $2.6 million the previous year [6] - Cash reserves improved significantly to $3.9 million at April 30, 2025, compared to $0.4 million at April 30, 2024, while total liabilities decreased to $0.6 million from $3.2 million [6] Clinical Advancements - Alzamend is advancing treatments for Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, primarily through its drug candidate AL001, which aims for safer and more effective lithium therapy [3][4] - The first of five Phase II clinical trials for AL001 began in May 2025, with topline results expected by the end of 2025 [4] Product Pipeline - The company is developing two therapeutic drug candidates: AL001, a lithium-salicylate/L-proline cocrystal, and ALZN002, an active immunotherapy product targeting amyloid-beta proteins [5][10] - ALZN002 is currently in a Phase I/IIA clinical trial to evaluate its safety and efficacy in patients with mild to moderate Alzheimer's [8]